Dr. Reddy's Laboratories Limited (BOM:500124)

Dr. Reddy's Laboratories Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	329,843	335,933	325,535	279,164	245,879	214,391
Revenue Growth	-3.60%	3.19%	16.61%	13.54%	14.69%	13.00%
Gross Profit Gross Profit Growth	163,241	177,264	190,428	163,607	139,343	113,840
Operating Income Operating Income Growth	30,201	49,246	72,014	65,308	53,416	35,919
Net Income Net Income Growth	27,986	42,850	56,544	55,684	45,067	23,568
Earnings Per Share EPS Growth	33.58	51.42	67.78	66.80	54.17	28.34
EPS Growth	-52.26%	-24.14%	1.47%	23.32%	91.16%	36.70%

Revenue by Segment

Chart

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Others Others Growth	2,127	2,137	3,910	3,042	4,481
Pharmaceutical Services and Active Ingredients (PSAI) Pharmaceutical Services and Active Ingredients (PSAI) Growth	42,043	43,235	40,580	36,518	36,995
Global Generics Global Generics Growth	299,033	289,552	245,453	213,768	179,170
Inter-Segment Revenues Inter-Segment Revenues Growth	-7,270	-9,389	-10,779	-7,449	-6,255
Total Total Growth	335,933	325,535	279,164	245,879	214,391

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	76,242	87,814	57,908	81,470	61,797	44,365
Total Debt Total Debt Growth	72,287	77,341	46,766	20,020	13,472	33,845
Net Cash (Debt) Net Cash Growth	3,955	10,473	11,142	61,450	48,325	10,520
Net Cash Growth	-64.92%	-6.00%	-81.87%	27.16%	359.36%	146.66%
Net Cash Per Share Net Cash Per Share Growth	4.75	12.57	13.36	73.72	58.09	12.65

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	30,910	56,755	46,428	45,433	58,875	28,108
Capital Expenditures CapEx Growth	-17,068	-23,326	-27,504	-16,403	-11,323	-14,660
Free Cash Flow Free Cash Flow Growth	13,842	33,429	18,924	29,030	47,552	13,448
Free Cash Flow Growth	-56.57%	76.65%	-34.81%	-38.95%	253.60%	-48.20%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	49.49%	52.77%	58.50%	58.61%	56.67%	53.10%
Operating Margin	9.16%	14.66%	22.12%	23.39%	21.73%	16.75%
Pretax Margin	10.68%	16.32%	23.59%	25.74%	24.55%	15.06%
Profit Margin	8.48%	12.76%	17.37%	19.95%	18.33%	10.99%
FCF Margin	4.20%	9.95%	5.81%	10.40%	19.34%	6.27%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 24, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	8.000	8.000	8.000	8.000	8.000	6.000
Dividend Per Share Growth	0%	0%	0%	0%	33.33%	20.00%
Dividend Yield	0.65%	0.64%	0.70%	0.65%	0.87%	0.70%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 24, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	36.46	24.38	16.86	18.41	17.03	30.32
Forward PE	23.84	21.35	15.36	19.12	19.56	23.75
P/FCF Ratio	73.69	31.25	50.37	35.31	16.14	53.13
PS Ratio	3.09	3.11	2.93	3.67	3.12	3.33

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error